Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
01/07/20181:01PMPRNUSNeurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief ...
Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer PR Newswire SAN DIEGO, Jan. 7, 2018 SAN DIEGO, Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine... More...>>
01/07/20181:00PMPRNUSNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones - Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017 - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales... More...>>
01/02/20184:01PMPRNUSNeurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference Live Audio Webcast Will be on January 8, 2018 PR Newswire SAN DIEGO, Jan. 2, 2018 SAN DIEGO, Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference... More...>>
12/14/20174:15PMBWPuma Biotechnology Added to NASDAQ Biotechnology Index
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market® (NASDAQ) that meet NBI’s eligibility criteria... More...>>
12/07/20171:15PMPRNUSNeurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Live Audio Webcast Will be on December 14, 2017 PR Newswire SAN DIEGO, Dec. 7, 2017 SAN DIEGO, Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets... More...>>
12/04/20174:01PMPRNUSNeurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Imp...
Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms - INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial - Additional... More...>>
11/29/20174:01PMPRNUSNeurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the Ame...
Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic PR Newswire SAN DIEGO, Nov. 29, 2017 SAN DIEGO, Nov... More...>>
11/21/20171:15PMPRNUSNeurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference Live Audio Webcast Will be on November 28, 2017 PR Newswire SAN DIEGO, Nov. 21, 2017 SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference... More...>>
11/21/20178:15AMGLOBEDetailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrin...
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nexstar Broadcasting Group, Inc. (NASDAQ:NXST), CECO Environmental Corp. (NASDAQ:CECE), Performance Food... More...>>
11/20/20174:01PMPRNUSNeurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer PR Newswire SAN DIEGO, Nov. 20, 2017 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining... More...>>
11/14/20171:34PMPRNUSNeurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in...
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry - Data from the KINECT 3 Phase III Extension Study Show INGREZZA (valbenazine) Maintained Improvement with Favorable Safety Profile in 52-week Trial PR Newswire... More...>>
11/09/20174:01PMPRNUSINGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Awar...
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association PR Newswire SAN DIEGO, Nov. 9, 2017 SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that... More...>>
11/08/20171:15PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference Live Audio Webcast Will be on November 16, 2017 PR Newswire SAN DIEGO, Nov. 8, 2017 SAN DIEGO, Nov. 8, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at... More...>>
11/07/20174:01PMPRNUSNeurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Educ...
Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress PR Newswire SAN DIEGO, Nov. 7, 2017 SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that data for INGREZZA® (valbenazine... More...>>
11/01/20174:01PMPRNUSNeurocrine Biosciences Reports Third Quarter 2017 Results
Neurocrine Biosciences Reports Third Quarter 2017 Results - INGREZZA® (valbenazine) Net Product Sales of $45.8 Million for Initial Full Quarter of Commercialization as the First U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Elagolix New Drug Application for Endometriosis... More...>>
11/01/201712:00PMPRNUSAbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometr...
AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain - In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse - No new... More...>>
10/31/20171:15PMPRNUSNeurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference
Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference Live Audio Webcast Will be on November 8, 2017 PR Newswire SAN DIEGO, Oct. 31, 2017 SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences... More...>>
10/27/20177:00AMPRNUSAbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with...
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain - FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease... More...>>
10/25/20174:01PMPRNUSNeurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome
Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome 12-Week T-Force GOLD Study to Assess the Safety, Tolerability, Efficacy and Optimal Dose of INGREZZA in Pediatric Patients PR Newswire SAN DIEGO, Oct. 25, 2017 SAN DIEGO, Oct. 25, 2017 /PRNewswire/... More...>>
10/24/20171:23PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results Conference Call and Webcast Scheduled for November 1, 2017 PR Newswire SAN DIEGO, Oct. 24, 2017 SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20180120 01:07:57